NetwoRx Bio

Revolutionizing immunotherapy trials with AI-driven drug–indication–biomarker insights.

Health Tech & Life Sciences
Active
Pre-Funding Tel Aviv-Yafo Founded 2024
Total raised
Stage
Pre-Funding
Founded
2024
Headcount
5
HQ
Tel Aviv-Yafo
Sector
Health Tech & Life Sciences

About

NetwoRx Bio is unlocking the next generation of immunotherapy. We harness cutting-edge computational biology to decode the complex communication networks between immune, tumor, and stromal cells within the tumor microenvironment—revealing how these interactions drive treatment response and resistance.

Powered by proprietary data from our clinical trials and advanced AI-driven analytics, we generate the NetwoRx Score: a patient-specific metric that identifies the most actionable molecular interactions. This score predicts response to immune checkpoint inhibitors (ICIs), monoclonal antibodies, and small molecule immune modulators—transforming complexity into precision.

Our Value Proposition:

1. Optimal Clinical Trial Design Matching the right immunotherapeutic drugs or combinations to the right indication and patient population—enhancing trial success and development efficiency.

2. Precision Medicine Delivering personalized immunotherapy by identifying which patients are most likely to benefit from specific treatments.

NetwoRx Bio turns the hidden communication networks of the tumor microenvironment into a roadmap for smarter, faster, and more effective immunotherapy.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life Sciences
Technologies
BiologicalsArtificial Intelligence
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B

Highlights

1 PatentsVerified

Tags

treatmentsimmunologyimmunotherapycancercancer-therapyoncology